Short-course antiretroviral therapy in primary HIV infection.
暂无分享,去创建一个
Steve Kaye | Kholoud Porter | Helen Rees | Abdel Babiker | Sabine Kinloch | Martin Fisher | John Frater | Rodney Phillips | Mauro Schechter | David Cooper | Pontiano Kaleebu | Sarah Fidler | H. Rees | P. Kaleebu | R. Phillips | J. Miro | D. Cooper | J. Weber | A. Kelleher | G. Ramjee | M. Schechter | A. Babiker | J. Frater | M. Mcclure | K. Porter | S. Fidler | Gita Ramjee | Jonathan Weber | Giuseppe Tambussi | G. Tambussi | M. Fisher | C. Wyen | Anthony Kelleher | S. Kaye | Fiona Ewings | Jose M Miro | Myra McClure | Michelle Gabriel | S. Kinloch | F. Ewings | M. Gabriel | David A. Cooper | Myra McClure | Sarah Fidler | J. Weber | G. Fätkenheuer | Clara Lehmann | Martin Fisher | Sabine Kinloch | Mauro Schechter | Abdel Babiker | Kholoud Porter | Fiona Ewings | Gita Ramjee | Helen Rees | J. M. Miro | Anthony D. Kelleher | Steve Kaye | Michelle Gabriel | Rodney E. Phillips
[1] C. B. Hare,et al. The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. , 2012, The Journal of infectious diseases.
[2] B. Berkhout,et al. In HIV-1 pathogenesis the die is cast during primary infection , 2007, AIDS.
[3] P. Kissinger,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.
[4] M. Prins,et al. Transient lowering of the viral set point after temporary antiretroviral therapy of primary HIV type 1 infection. , 2010, AIDS research and human retroviruses.
[5] Sigall K. Bell,et al. Clinical management of acute HIV infection: best practice remains unknown. , 2010, The Journal of infectious diseases.
[6] B. Gazzard,et al. Initiation of Antiretroviral Therapy During Recent HIV-1 Infection Results in Lower Residual Viral Reservoirs , 2004, Journal of acquired immune deficiency syndromes.
[7] Anthony D. Kelleher,et al. Human Immunodeficiency Virus Type 1-Specific CD8+ T-Cell Responses during Primary Infection Are Major Determinants of the Viral Set Point and Loss of CD4+ T Cells , 2009, Journal of Virology.
[8] Lei Wang,et al. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. , 2006, The Journal of infectious diseases.
[9] Peter Reiss,et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. , 2008, JAMA.
[10] C. Speil. Incomplete Peripheral CD4+ Cell Count Restoration in HIV-Infected Patients Receiving Long-Term Antiretroviral Treatment , 2009 .
[11] C. Tremblay,et al. Effect of antiretroviral therapy on HIV-1 genetic evolution during acute infection , 2011, International journal of STD & AIDS.
[12] Jeffrey N. Martin,et al. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] Michael P Busch,et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection , 2003, AIDS.
[14] H. Schuitemaker,et al. No Treatment versus 24 or 60 Weeks of Antiretroviral Treatment during Primary HIV Infection: The Randomized Primo-SHM Trial , 2012, PLoS medicine.
[15] J. Parry,et al. Assays for the detection of recent infections with human immunodeficiency virus type 1. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[16] P. Easterbrook,et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[17] James M Robins,et al. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals , 2010, AIDS.
[18] E. Rosenberg,et al. Human Immunodeficiency Virus Type 1-Specific CD8+ T-Cell Responses during Primary Infection Are Major Determinants of the Viral Set Point and Loss of CD4+ T Cells , 2009, Journal of Virology.
[19] M. Altfeld,et al. Acute HIV-1 infection: what's new? Where are we going? , 2010, The Journal of infectious diseases.
[20] A. Walker,et al. Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy , 2007, AIDS.
[21] S. Khoo,et al. Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] J. Ananworanich,et al. Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs , 2005, AIDS.
[23] A. Phillips,et al. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. , 2008, Annals of internal medicine.
[24] M. McElrath,et al. Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection. , 2000, The Journal of infectious diseases.
[25] K. Metzner,et al. Profound Depletion of HIV-1 Transcription in Patients Initiating Antiretroviral Therapy during Acute Infection , 2010, PloS one.
[26] B. Haynes,et al. Acute HIV-1 Infection. , 2011, The New England journal of medicine.
[27] H. Günthard,et al. Effect of Early Antiretroviral Therapy during Primary HIV-1 Infection on Cell-Associated HIV-1 Dna and Plasma HIV-1 Rna , 2011, Antiviral therapy.
[28] J. Weber,et al. Human immunodeficiency virus (HIV)‐specific T helper responses fail to predict CD4+ T cell decline following short‐course treatment at primary HIV‐1 infection , 2008, Clinical and experimental immunology.
[29] Tommy F. Liu,et al. Web resources for HIV type 1 genotypic-resistance test interpretation. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[30] B. Walker,et al. Characterization of HIV-1-specific T-helper cells in acute and chronic infection. , 1999, Immunology letters.
[31] A Muñoz,et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. , 1998, JAMA.
[32] Elizabeth Connick,et al. Immunophenotypic alterations in acute and early HIV infection. , 2007, Clinical immunology.
[33] G. Satten,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.
[34] J. Weber,et al. Primary HIV infection: to treat or not to treat? , 2008, Current opinion in infectious diseases.
[35] F. A. Monteiro. O Abandono do Monumento: O Caso do Hospital Escola São Francisco de Assis , 2014 .
[36] Kholoud Porter,et al. Determinants of survival following HIV-1 seroconversion after the introduction of HAART , 2003, The Lancet.